BOH-2C-B, or BOHB, also known as 4-bromo-2,5-dimethoxy-ò-hydroxyphenethylamine or as ò-hydroxy-2C-B, is a psychedelic drug of the phenethylamine, 2C, and BOx families. It is the ò-hydroxy derivative of 2C-B. The drug has been encountered as a novel designer drug.
BOH-2C-B was not included or mentioned in Alexander Shulgin's book PiHKAL (Phenethylamines I Have Known and Loved). Subsequently, Daniel Trachsel listed BOHB's dose as 30mg or more orally in his book Phenethylamine: von der Struktur zur Funktion (Phenethylamines: From Structure to Function).
BOH-2C-B acts as a serotonin 5-HT<sub>2A</sub> receptor agonist.
BOH-2C-B is a substituted phenethylamine. It features methoxy substituents at the 2- and 5-position of the ring, as well as a bromine at the 4-position. A hydroxy group is present at the beta (ò) position from the functional amine group connected to the alpha (ñ) carbon, giving rise to its name.
Analogues of BOH-2C-B include 2C-B, BOB (ò-methoxy-2C-B), òk-2C-B (ò-keto-2C-B), ò-methyl-2C-B, BOHD (ò-hydroxy-2C-D), and BOD (ò-methoxy-2C-D), among others.
BOH-2C-B was first described in a 2004 study by Richard Glennon and colleagues on ò-oxygenated 5-HT<sub>2A</sub> serotonin receptor agonists, although it is not mentioned by name. It was encountered as a novel designer drug in 2019. However, it is said to have been on the market since 2015.
BOH-2C-B is a controlled substance in the following countries: